Pirmenol

Research use only, not for human use.

Pirmenol is?a new antiarrhythmic drug.

Pirmenol is?a new antiarrhythmic drug.(In Vitro):Pirmenol (1 μM) hydrochloride inhibits the IK.ACh induced by carbachol or intracellular loading of GTPg S in in atrial cells.Pirmenol (5 μM) hydrochloride depresses the early part of the plateau and lengthened the final repolarization of the action potentials in ventricular myocytes.Pirmenol (1 μM) hydrochloride prolongs the action potential duration at 90% repolarization in atrial muscles and Purkinje fibers.(In Vivo):Pirmenol (2.5 and 5 mg/kg, p.o.) hydrochloride is effective against the arrhythmias in conscious, coronary artery ligated dogs.Pirmenol (rats) hydrochloride shows LD50s of 359.9 mg/kg (p.o), 23.6 mg/kg (i.v.).Pirmenol (mice) hydrochloride shows LD50s of 215.5 mg/kg (p.o), 20.8 mg/kg (i.v.).

Pirmenol (1 μM) inhibits the IK.ACh induced by carbachol or intracellular loading of GTPg S in in atrial cells.Pirmenol (5 μM) depresses the early part of the plateau and lengthened the final repolarization of the action potentials in ventricular myocytes.Pirmenol (1 μM) prolongs the action potential duration at 90% repolarization in atrial muscles and Purkinje fibers.

Pirmenol (2.5 and 5 mg/kg, p.o.) is effective against the arrhythmias in conscious, coronary artery ligated dogs.Pirmenol (rats) shows LD50s of 359.9 mg/kg (p.o), 23.6 mg/kg (i.v.).Pirmenol (mice) shows LD50s of 215.5 mg/kg (p.o), 20.8 mg/kg (i.v.). Animal Model:Conscious, coronary artery ligated dogs Dosage:Oral administration (p.o.)Administration:2.5 and 5 mg/kg Result:Restored normal sinus rhythm, and showed a long duration of activity, wide safety margin.

——

Others

Other Targets

Others

——

——

68252-19-7

338.49

C22H30N2O

>98% (HPLC)

——

C[C@H]1CCC[C@@H](C)N1CCCC(O)(c1ccccc1)c1ccccn1

4-((2R6S)-26-dimethylpiperidin-1-yl)-1-phenyl-1-(pyridin-2-yl)butan-1-ol

(-20℃)

With Ice Pack

≥ 2 years